finip

Comments (0)

Transcript of finip

Data published in The Lancet show GlaxoSmithKline’s PCV is highly effective at preventing invasive pneumococcal disease First randomised controlled European clinical trial of a pneumococcal conjugate vaccine (PCV) to examine impact on invasive pneumococcal disease (IPD) GlaxoSmithKline's PCV is highly effective (93-100%) at preventing IPD in infants younger than 2 years of age, who are most vulnerable to infection. With 47,369 children enrolled, this is the largest IPD effectiveness trial of PCVs in children. Finnish Invasive Pneumococcal Disease Vaccine Trial (FinIP) was conducted nationwide and tracked GSK's PCV effectiveness over a two-year period on average. The results show that GSK's PCV was highly effective when administered in either a three-dose (2+1) or a four-dose (3+1) schedule to infants starting at less than seven months of age (infants received two or three doses in their first year and a booster at 2 years of age). For the first time in a clinical trial setting, effectiveness of a PCV utilised according to the infant 2+1 schedule, as used in many national immunisation programmes, was demonstrated (92% against vaccine type IPD). “IPD causes illness, hospitalisation and even death in Finnish children and across the world. These significant data show that GSK's PCV is an important public health tool in helping to reduce the burden of the disease.” Vice President and Vaccine Development Leader for Pneumococcal Vaccines, GSK Vaccines Vaccine-preventable IPD, such as meningitis, bacteraemic pneumonia and sepsis, causes death and illness in young children worldwide. The results from this randomised controlled clinical trial are also confirmed in post-implementation surveillance from four continents around the world, which show consistent robust effectiveness against IPD, following vaccination with GSK's PCV. Press Release - IPD caused by vaccine serotypes in a 3+1 schedule was 100%.

- overall IPD, regardless of pneumococcal serotypes, was 93%. GSK's PCV effectiveness against No safety concerns were noted during the study. In addition, high effectiveness was observed in different catch-up schedules for older children. References: